This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA Program 93.859 Biomedical Research and Research Training, provides $757,299 to Abbratech Inc. to develop a comprehensive platform for identifying and validating recombinant antibodies specific to protein isoform splice-junction sites. The key products and services to be delivered under this "Directed Discovery and Validation of Anti-Splice-Junction Site Antibodies" project include: 1)...
Codomax Inc., a biotechnology company, received a $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350. The funding supports Codomax's research and development to optimize antibody production in Chinese Hamster Ovary (CHO) cells using its proprietary EPI-MAX technology platform. The project aims to enhance heavy and light chain expression by analyzing tRNA systems that limit antibody production and re-engineering the CREB1...
This $842,151 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of an improved, low-endotoxin E. coli strain for the production of biological products such as recombinant proteins and plasmid DNA. The awardee, Scarab Genomics LLC, a biotechnology company in Madison, Wisconsin, will use genetic engineering techniques to substantially lower the level of contaminating endotoxin...
The National Science Foundation awarded Opera Bioscience, Inc. $275,000 under the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a low-cost bacterial production platform for manufacturing high purity recombinant proteins and growth factors. The award period runs from June 15, 2023 through May 31, 2024. Opera Bioscience will utilize this funding to demonstrate the ability of its innovative protein production platform to solve challenges in traditionally costly and...
This Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) provides $379,730 to the University of North Carolina at Chapel Hill to develop a continuous electrochemical sensor for monitoring therapeutic monoclonal antibodies, using the FDA-approved drug bevacizumab as an example. The research aims to overcome challenges in discriminating between therapeutic antibodies and human IgG in biological fluids, and in regenerating the aptamer binding site for...
This Project Grant award of $1,000,000 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of Partillion Bioscience Corp's advanced antibody discovery workflows. The funding aims to enhance their specialized hydrogel microparticle technology called "nanovials" to enable ultra high-throughput screening and functional assessment of single B cells and antibody-secreting cells. This is expected...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop foundational data science methods and a pipeline for efficient and exceptional monoclonal antibody (mAb) formulation. The $342,776 award to Rutgers, The State University, will fund a project focused on using artificial intelligence/machine learning (AI/ML) and...
Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
This $256,000 National Science Foundation project grant supports the generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies by Welt Bio-Molecular Pharmaceutical, LLC. The grant funds research under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop novel monoclonal antibody therapies that could provide more affordable and less toxic options for leukemias and lymphomas compared to current drugs. Specifically, the awardee...